Search over 3,000 reports

    Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017

    Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017
    Date: Sep, 2017
    Type: Pharmaceutical Industry Report
    Pages:
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0015

    DelveInsight’s, “Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017” report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action. The report provides information on all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. Furthermore, the report also contains detailed information of marketed products along with historical and forecasted sales.

    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

    The report comprehensively includes:

    • In-depth analysis of the 28+ pipeline assets and 5 marketed products
    • Therapeutic assessment by molecule type, route of administration, monotherapy and combination products
    • Licensing, Deals and Patent details (marketed and pipeline) related to HDAC inhibitors are also covered
    • Insights on marketed products including detailed marketed product profiles. Also, includes Historical and Forecasted sales for Marketed products
    • Information on various technologies involved in the development of pipeline therapeutics along with drug designations is also provided
     

    Executive Summary

    Overview

    Competitive Landscape

    Collaboration

    Technology

    Designation

    Active Pipeline coverage by Indication

    Marketed and Pipeline Drugs

    Marketed Drug Profiles

    Farydak: Novartis

    Product Description

    Regulatory Milestones

    Research and Development

    Other Clinical Activities

    Product Development Activities

    Farydak Global Sales

    Farydak Analyst Insights

    Beleodaq: Spectrum Pharmaceuticals

    Product Description

    Regulatory Milestones

    Research and Development

    Other Clinical Activities

    Product Development Activities

    Beleodaq Global Sales

    Beleodaq Analyst Insights

    Epidaza: Chipscreen Bioscience

    Product Description

    Regulatory Milestones

    Research and Development

    Other Clinical Activities

    Product Development Activities

    Epidaza Analyst Insights

    Zolinza: Merck

    Product Description

    Regulatory Milestones

    Research and Development

    Other Clinical Activities

    Product Development Activities

    Zolinza Global Sales

    Zolinza Analyst Insights

    Istodax: Gloucester Pharmaceuticals

    Product Description

    Regulatory Milestones

    Research and Development

    Other Clinical Activities

    Product Development Activities

    Istodax Global Sales

    Istodax Analyst Insights

    Market Positioning of HDAC Inhibitors

    HDAC Inhibitors Market Evaluation

    HDAC Inhibitors Class Share Evaluation

    Pipeline Therapeutics

    Comparative Analysis

    Late Stage Products (Phase III)

    Comparative Analysis

    Entinostat: Syndax Pharmaceuticals

    Product Description

    Research and Development

    Product Development Activities

    Pracinostat: MEI Pharma

    Product Description

    Research and Development

    Product Development Activities

    Givinostat: Italfarmaco

    Product Description

    Research and Development

    Product Development Activities

    Mid-Stage Products (Phase II)

    Comparative Analysis

    Mocetinostat: Mirati Therapeutic

    Product Description

    Research and Development

    Product Development Activities

    Quisinostat: Janssen

    Product Description

    Research and Development

    Product Development Activities

    VRx-3996: Viracta Therapeutics

    Product Description

    Research and Development

    Product Development Activities

    Sulforadex: Evgen Pharma

    Product Description

    Research and Development

    Product Development Activities

    CHR 5154: Chroma Therapeutics

    Product Description

    Research and Development

    Product Development Activities

    CUDC 907: Curis

    Product Description

    Research and Development

    Product Development Activities

    Ricolinostat: Celgene Corporation

    Product Description

    Research and Development

    Product Development Activities

    Remetinostat: TetraLogic Pharmaceuticals

    Product Description

    Research and Development

    Product Development Activities

    Abexinostat: Celera Genomics Group

    Product Description

    Research and Development

    Product Development Activities

    Resminostat: 4SC

    Product Description

    Research and Development

    Product Development Activities

    FRM 0334: FORUM Pharmaceuticals

    Product Description

    Research and Development

    Product Development Activities

    Early Stage Products (Phase I)

    Comparative Analysis

    Citarinostat: Celgene Corporation

    Product Description

    Research and Development

    Product Development Activities

    AR-42: Arno Therapeutics

    Product Description

    Research and Development

    Product Development Activities

    EDO S101: Mundipharma International

    Product Description

    Research and Development

    Product Development Activities

    Pre-clinical Products

    Comparative Analysis

    PCI-34051: Pharmacyclics

    Product Description

    Research and Development

    Product Development Activities

    HG 3001: HitGen

    Product Description

    Research and Development

    Product Development Activities

    CG-1255: CircaGen Pharmaceutical

    Product Description

    Research and Development

    Product Development Activities

    CG-1521: CircaGen Pharmaceutical

    Product Description

    Research and Development

    Product Development Activities

    Trichostatin A: Errant Gene Therapeutics

    Product Description

    Research and Development

    Product Development Activities

    QTX-125: Quimatryx

    Product Description

    Research and Development

    Product Development Activities

    QTX-153: Quimatryx

    Product Description

    Research and Development

    Product Development Activities

    ACY 1083: Regenacy Pharmaceuticals

    Product Description

    Research and Development

    Product Development Activities

    ACY-738: Celgene Corporation

    Product Description

    Research and Development

    Product Development Activities

    Therapeutic Assessment

    Assessment by Monotherapy Products

    Assessment by Route of Administration

    Assessment by Stage and Route of Administration

    Assessment by Molecule Type

    Assessment by Stage and Molecule Type

    Institutional Products

    Inactive Products

    Comparative Analysis

    Market Drivers and Barriers

    Appendix

     

    Table 1: Active Pipeline Coverage by Indication 
    Table 2: Marketed and Pipeline HDAC Inhibitors
    Table 3: Total Products for HDAC Inhibitors 
    Table 4: Late Stage Products (Phase III)
    Table 5: Mid Stage Products (Phase II)
    Table 6: Pre-clinical Products
    Table 7: Assessment by Monotherapy Products
    Table 8: Assessment by Route of Administration 
    Table 9: Assessment by Stage and Route of Administration
    Table 10: Assessment by Molecule Type
    Table 11: Assessment by Stage and Molecule Type 
    Table 12: Dormant Products
    Table 13: Discontinued Products

    Figure 1: Structure of HDAC Inhibitors
    Figure 2: Mechanism of HDAC Inhibitors
    Figure 3: Marketed and Pipeline HDAC Inhibitors
    Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
    Figure 5: Market Evolution (2015-2023)
    Figure 6: Total Active Products for HDAC Inhibitors
    Figure 7: Total Products for HDAC Inhibitors
    Figure 8: Late Stage Products (Phase III)
    Figure 9: Entinostat Forecasted Sales (2019-2023)
    Figure 10: Mid Stage Products (Phase II) 
    Figure 11: Early Stage Products (Phase I)
    Figure 12: Pre-clinical Products
    Figure 13: Assessment by Monotherapy Products
    Figure 14: Assessment by Route of Administration
    Figure 15: Assessment by Stage and Route of Administration 
    Figure 16: Assessment by Molecule Type
    Figure 17: Assessment by Stage and Molecule Type
    Figure 18: Inactive Products

     

    • Single User Price
      $3,250.00
    • Site License Price
      $6,500.00
    • Enterprise Price
      $9,750.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap